Keywords: دارنویور; Overweight; Body composition; Antiretroviral drugs; Drug monitoring; Efavirenz; Atazanavir; Darunavir;
مقالات ISI دارنویور (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: دارنویور; Darunavir; Bovine serum albumin; Interaction; Spectroscopy; Molecular docking;
Keywords: دارنویور; HIV; Darunavir; IMT;
Keywords: دارنویور; in vitro/in vivo correlations (IVIVC); hepatic transport; hepatic metabolism; hepatic clearance; hepatocytes; HIV/AIDS; membrane transport; metabolism; organic anion-transporting polypeptide transporters; APV; amprenavir; ATV; atazanavir; CHO; Chinese h
Keywords: دارنویور; 3TC; Lamivudine; ABC; Abacavir; ARV; Antiretroviral; ATV; Atazanavir; AZT; Zidovudine; d4T; Stavudine; DRV; Darunavir; EFV; Efavirenz; FTC; Emtricitabine; L&D; Labor and delivery; LOQ; Limit of quantification; LPV; Lopinavir; M8; NFV hydroxy-tert-butylami
Keywords: دارنویور; Ritonavir; Darunavir; Solid dispersion; Spray drying; Cyclodextrins; Solubility
Keywords: دارنویور; Elvitegravir; Tenofovir; Cobicistat; Darunavir; Food; Therapeutic drug monitoring
Therapeutic drug monitoring in treatment-experienced HIV-infected patients receiving darunavir-based salvage regimens: A case series
Keywords: دارنویور; Therapeutic drug monitoring; Darunavir; Etravirine; Raltegravir; Instantaneous inhibitory potential; Genotypic inhibitory quotient;
Darunavir alleviates irinotecan-induced intestinal toxicity in Vivo
Keywords: دارنویور; Darunavir; Irinotecan; Inflammation; HMGB1; NLRP3;
Exploring the feasibility of the use of biopolymers as a carrier in the formulation of amorphous solid dispersions - Part I: Gelatin
Keywords: دارنویور; Carbamazepine (2554); Cinnarizine (1547484); Darunavir (Ethanolate: 23725083); Fenofibrate (3339); Griseofulvin (441140); Indomethacin (3715); Itraconazole (55283); Ketoconazole (456201); Naproxen (156391); Nifedipine (4485); Ritonavir (392622); Diazepam
Multi-spectroscopic and molecular docking studies on the interaction of darunavir, a HIV protease inhibitor with calf thymus DNA
Keywords: دارنویور; Calf thymus DNA; Darunavir; Groove binding; Spectroscopy; Molecular docking;
Research paperEncapsulating darunavir nanocrystals within Eudragit L100 using coaxial electrospraying
Keywords: دارنویور; Nanocrystals; Electrospraying; Darunavir; Enteric coating;
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort
Keywords: دارنویور; HIV; Cardiovascular risk; Atherosclerosis; Darunavir; Atazanavir; Efavirenz;
Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC–MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a pote
Keywords: دارنویور; LC–MS/MS; Intracellular; Anti-retroviral drugs; HIV-1; Drug interaction; Darunavir; Etravirine; PBMCs
LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulation
Keywords: دارنویور; Vascular smooth muscle cells; ZMPSTE24; Prelamin A; Senescence; Osteogenic transdifferentiation; Atherosclerosis; ALP; alkaline phosphatase; ATV; atazanavir; DRV; darunavir; HIV; human immunodeficiency virus; LPV; lopinavir; M/R; maraviroc/raltegravir; PB
Development and validation of a selective, sensitive and stability indicating UPLC-MS/MS method for rapid, simultaneous determination of six process related impurities in darunavir drug substance
Keywords: دارنویور; Antiretroviral drugs; Darunavir; Process related impurities; Hyphenated techniques; Linearity; Protease inhibitors;
Direct injection HILIC–MS/MS analysis of darunavir in rat plasma applying supported liquid extraction
Keywords: دارنویور; Darunavir; HILIC–MS/MS; Rat plasma; Supported liquid extraction
Solid self-nanoemulsifying drug delivery system (S-SNEDDS) of darunavir for improved dissolution and oral bioavailability: In vitro and in vivo evaluation
Keywords: دارنویور; Darunavir; Solid self-nanoemulsifying drug delivery system; Dissolution; Globule size; Bioavailability;
Interpatient variability of darunavir concentrations in plasma during long-term antiretroviral monotherapy
Keywords: دارنویور; Antiretroviral therapy; Darunavir; HPLC; Therapeutic drug monitoring
LC–MS/MS structural characterization of stress degradation products including the development of a stability indicating assay of Darunavir: An anti-HIV drug
Keywords: دارنویور; Darunavir; Anti-retroviral; AIDS; Forced degradation; LC–MS/MS
LC–Q-TOF-MS/MS determination of darunavir and its metabolites in rat serum and urine: Application to pharmacokinetics
Keywords: دارنویور; Darunavir; Rat serum; Urine; Selective ion monitoring; Pharmacokinetics
Comparative analysis of ER stress response into HIV protease inhibitors: Lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway
Keywords: دارنویور; APV; Amprenavir; ARE; antioxidant response; ATV; Atazanavir; cART; Combination antiretroviral therapy; DRV; Darunavir; FDA; Food and Drug Administration; IDV; Indinavir; LDH; lactate dehydrogenase; LPV; Lopinavir; NAC; N-acetyl-L-cysteine; NFV; Nelfinavir
Keywords: دارنویور; adverse effects; antiretroviral therapy; atazanavir; darunavir; health care costs; Medicaid
Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)
Keywords: دارنویور; HIV; Safety; Darunavir; Antiretroviral therapy; Protease inhibitors
Site dependent intestinal absorption of darunavir and its interaction with ketoconazole
Keywords: دارنویور; Darunavir; P-gp; P450; Ketoconazole; Site dependent absorption; In situ perfusion
RP-HPLC separation and characterization of unknown impurities of a novel HIV-protease inhibitor Darunavir by ESI-MS and 2D NMR spectroscopy
Keywords: دارنویور; Antiretrovirals; Darunavir; Process related substances; RP-HPLC; 2D-NMR
High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil
Keywords: دارنویور; Highly active antiretroviral therapy; Darunavir; Acquired immunodeficiency syndrome; Developing countries
Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients
Keywords: دارنویور; Darunavir; Raltegravir; Ritonavir; Pharmacokinetics; Drug-to-drug interactions; HIV;
Efectividad y seguridad de la terapia de rescate en pacientes VIH
Keywords: دارنویور; Efectividad; Seguridad; Enfuvirtida; Darunavir; Tipranavir; Etravirina; VIH; Paciente multirresistente; Pauta de rescate; Effectiveness; Safety; Enfuvirtide; Darunavir; Tipranavir; Etravirine; HIV; Multidrug-resistant patients; Salvage therapy;
High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba
Keywords: دارنویور; ART; antiretroviral therapy; CI; confidence interval; NRTI; nucleoside reverse transcriptase inhibitor; NNRTI; non-nucleoside RTI; PI; protease inhibitor; FCR; full-class resistance; CRF; circulating recombinant form; HIV; human immunodeficiency virus; MD
Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir
Keywords: دارنویور; Salvage therapy; Antiretrovirals; Drug resistance; Darunavir; Raltegravir; Etravirine; Human immunodeficiency virus type 1;
The higher barrier of darunavir and tipranavir resistance for HIV-1 protease
Keywords: دارنویور; Darunavir; Tipranavir; Multi-drug resistant HIV-1 protease; X-ray crystallography;
Desarrollo y validación de un método para la determinación de darunavir en plasma mediante LC-MS/MS
Keywords: دارنویور; Darunavir; Inhibidor de proteasa; Tratamiento antirretroviral; Monitorización farmacocinética; LC/MS/MS; Darunavir; Protease inhibitor; Antiretroviral treatment; HIV; Pharmacokinetics monitoring; LC/MS/MS;
Indicación de uso de los antirretrovirales de última generación en la práctica clÃnica actual
Keywords: دارنویور; Darunavir; Maraviroc; Etravirina; Raltegravir; Resistencia multiple a medicamentos; Tratamiento antirretroviral; Infección por VIH; Darunavir; Maraviroc; Etravirine; Raltegravir; Multiple drug resistance; Antiretroviral treatment; HIV infection;
Application of a validated ultra performance liquid chromatography–tandem mass spectrometry method for the quantification of darunavir in human plasma for a bioequivalence study in Indian subjects
Keywords: دارنویور; Darunavir; UPLC–MS/MS; Human plasma; Bioequivalence study; Incurred sample reanalysis
Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study)
Keywords: دارنویور; HIV; Darunavir; Triple-class drug resistance; Raltegravir; Enfuvirtide; Etravirine
Meta-análisis sobre la eficacia de la estrategia de monoterapia con inhibidores de la proteasa potenciados en pacientes VIH+
Keywords: دارنویور; Inhibidores de proteasa; Meta-análisis; Ritonavir potenciado; Lopinavir; Darunavir; Ritonavir; HIV protease inhibitors; Meta-Analysis; Boosted ritonavir; Lopinavir; Darunavir; Ritonavir;
Improved bioavailability of darunavir by use of κ-carrageenan versus microcrystalline cellulose as pelletisation aid
Keywords: دارنویور; Bioavailability; Darunavir; TMC114; Carrageenan; Microcrystalline cellulose; Pellets; Extrusion; Spheronisation
A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma
Keywords: دارنویور; Etravirin; Darunavir; Ritonavir; HIV; Antiretroviral agent; Mass spectrometry;
A LC–tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine
Keywords: دارنویور; Integrase inhibitors; CCR5 co-receptor antagonists; Protease inhibitors; Non-nucleoside reverse transcriptase inhibitors; HPLC–MS/MS; Raltegravir; Maraviroc; Darunavir; Etravirine; Ritonavir
Darunavir, promising option in therapy multi-experience HIV-infected patients
Keywords: دارنویور; protease inhibitor; darunavir; HIV resistance;
Development of an implantable infusion pump for sustained anti-HIV drug administration
Keywords: دارنویور; Infusion pump; HIV; Protease inhibitor; Darunavir; Experimental; Continuous infusion; Viscous solution; Codman® pump
Dog model with implanted pump to test boosters for antiretroviral medication
Keywords: دارنویور; Infusion pump; HIV; Protease inhibitor; Darunavir; Booster; Experimental
New treatment options for HIV salvage patients: An overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists
Keywords: دارنویور; Salvage therapy; Etravirine; Tipranavir; Darunavir; Raltegravir; Maraviroc
Development of therapeutics for AIDS: Structure-based molecular targeting
Keywords: دارنویور; Chemotherapeutics for HIV/AIDS; Antiretroviral therapy; CCR5 inhibitors; Darunavir
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV
Keywords: دارنویور; Protease inhibitors; Darunavir; Design and synthesis
Quantification of darunavir (TMC114) in human plasma by high-performance liquid chromatography with ultra-violet detection
Keywords: دارنویور; TMC114; Darunavir; Liquid chromatography; UV detection
Ultra-high Resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114
Keywords: دارنویور; HIV-1, human immunodeficiency virus type 1; PR, protease; PI, protease inhibitor; DMSO, dimethylsulfoxideHIV-1 protease; drug resistance; darunavir; allosteric binding site; ultra-high resolution crystal structure